Impact of SGLT2 Inhibitors in Heart Transplant Recipients

Status Not yet recruiting

Clinical Trial Summary

The goal of this clinical trial is to test if SGLT2 inhibitors could prevent or delay the development of Cardiac Allograft Vasculopathy (CAV) post-heart transplantation (TxC). The main questions it aims to answer are: Primary outcome: CAV, according to ISHLT grading system diagnosed by CCTA; Secondary outcomes: cardiovascular death, all-cause mortality, hospitalization, worsening glomerular filtration rate, fasting glucose, weight, and blood pressure. Exploratory and safety outcomes: Rejection, hypoglycemia, urinary tract infection, hypovolemia, and limb amputation. HYPOTHESIS The null hypothesis is that SGLT2 inhibitors do not reduce the incidence of CAV in transplanted patients. The alternative hypothesis is that SGLT2 inhibitors reduce the incidence of CAV in transplanted patients.METHODOLOGY Study Design A randomized clinical trial of superiority with active control (2 arms), with central randomization and blinded evaluation of outcomes, to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to conventional post-TxC treatment compared with the treatment of isolated conventional post-TxC for 6-8 months. Study Sample Sample: All adult patients undergoing a heart transplant between January 2017 and December 2023 at Hospital de Messejana. Inclusion Criteria Included: Patients of both sexes, aged ≥ 18 years, who have undergone heart transplantation between January 2017 and December 2023 and are under the care of the Heart Transplant and Heart Failure Unit at Hospital de Messejana.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06147271
Study type	Interventional
Source	Universidade Federal do Ceara
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	November 20, 2023
Completion date	August 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02880137` - Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy	Phase 4
Terminated	`NCT01848301` - Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation	Phase 1
Terminated	`NCT01278745` - Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation	Phase 2
Withdrawn	`NCT01812434` - Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients	N/A
Withdrawn	`NCT01305382` - Noninvasive Evaluation of Cardiac Allograft Vasculopathy	N/A
Recruiting	`NCT05826444` - Microvascular Cardiac Allograft Vasculopathy Trial
Suspended	`NCT05756088` - Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
Completed	`NCT02013037` - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation	Phase 3
Withdrawn	`NCT01157949` - A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)	Phase 3
Withdrawn	`NCT01305395` - Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients	N/A
Recruiting	`NCT04193306` - Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients	Phase 4
Recruiting	`NCT02798731` - Physiologic Assessment of Microvascular Function in Heart Transplant Patients
Withdrawn	`NCT02777255` - Severe CAV MRI in Heart Transplant Recipient	N/A
Completed	`NCT05373108` - Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)	Phase 4
Withdrawn	`NCT01424917` - Noninvasive Predictors of Transplant Vasculopathy	N/A
Recruiting	`NCT04770012` - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation	Phase 3
Active, not recruiting	`NCT01078363` - Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy	N/A
Completed	`NCT03734211` - Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients	Phase 3
Recruiting	`NCT06089486` - MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation	N/A
Active, not recruiting	`NCT03386539` - Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score	Phase 3